Evoq Remedies IPO vs SP Refractories IPO

Comparison between Evoq Remedies IPO and SP Refractories IPO.

IPO Details

Evoq Remedies IPO is a SME Fixed Price IPO proposed to list at BSE SME while SP Refractories IPO is a SME Fixed Price proposed to list at NSE SME.

Issue Size and Price

The total issue size of Evoq Remedies IPO is up to ₹9.23 Cr whereas the issue size of the SP Refractories IPO is up to ₹4.67 Cr. The final issue price of Evoq Remedies IPO is ₹27.00 per share and of SP Refractories IPO is ₹90.00 per share.

 Evoq Remedies IPOSP Refractories IPO
Face Value₹10 per share₹10 per share
Issue Price (Final)₹27.00 per share₹90.00 per share
Discount (Retail)₹0.00 per share₹0.00 per share
Market Lot Size4000 shares1600 shares
Fresh Issue Size34,20,000 shares2,68,800 shares
Fresh Issue Size (Amount)up to ₹9.23 Crup to ₹2.42 Cr
OFS Issue Size0 shares2,49,600 shares
OFS Issue Size (Amount)up to ₹0.00 Crup to ₹2.25 Cr
Issue Size Total34,20,000 shares5,18,400 shares
Issue Size Total (Amount)up to ₹9.23 Crup to ₹4.67 Cr

IPO Timetable

Evoq Remedies IPO opens on Mar 17, 2022, while SP Refractories IPO opens on Mar 09, 2022. The closing date of Evoq Remedies IPO and SP Refractories IPO is Mar 22, 2022, and Mar 11, 2022, respectively.

 Evoq Remedies IPOSP Refractories IPO
Issue OpenMar 17, 2022Mar 09, 2022
Issue CloseMar 22, 2022Mar 11, 2022
Basis Of Allotment (Tentative)Mar 25, 2022Mar 16, 2022
Initiation of Refunds (Tentative)Mar 28, 2022Mar 17, 2022
Credit of Share (Tentative)Mar 29, 2022Mar 21, 2022
Listing date (Tentative)Mar 30, 2022Mar 22, 2022

Financials & KPIs

Evoq Remedies IPO P/E ratio is 33.75, as compared to SP Refractories IPO P/E ratio of 9.94.

 Evoq Remedies IPOSP Refractories IPO
Financials

Company Financials (Restated)

Period Ended10 Feb 202231 Mar 202131 Mar 202031 Mar 2019
Assets26.618.055.652.15
Total Income10.5710.029.073.25
Profit After Tax0.940.710.000.01
EBITDA1.250.950.000.02
NET Worth13.280.740.020.02
Reserves and Surplus3.280.730.010.01
Total Borrowing5.730.010.010.00
Amount in ₹ Crore

Company Financials (Restated)

Period Ended30 Sep 202131 Mar 202131 Mar 202031 Mar 2019
Assets12.3210.578.987.92
Total Income14.4825.7221.0018.56
Profit After Tax0.810.750.400.21
EBITDA1.341.491.220.90
NET Worth5.484.673.923.52
Reserves and Surplus3.993.183.423.02
Total Borrowing3.953.794.133.75
Amount in ₹ Crore
Promoter Shareholding (Pre-Issue)99.99%100%
Promoter Shareholding (Post-Issue)73.53%69.42%
P/E Ratio33.759.94
Market Cap₹36.72 Cr.₹16.11 Cr.
Debt/Equity0.81
EPS₹10.05₹5.05
RoNW96.9416.13

Shares Offered

In the Evoq Remedies IPO Retail Individual Investors (RII) are offered 17,10,000 shares while in SP Refractories IPO retail investors are offered 17,10,000 shares. Qualified Institutional Buyers (QIB) are offered in Evoq Remedies IPO and 0 shares in SP Refractories IPO.

 Evoq Remedies IPOSP Refractories IPO
Anchor Investor Reservation0 shares
Market Maker Reservation1,80,000 shares28,800 shares
QIB0 shares
NII17,10,000 shares2,59,200 shares
RII17,10,000 shares2,59,200 shares
Employee0 shares
Total34,20,000 shares5,18,400 shares

Bids Received (Subscription)

Evoq Remedies IPO subscribed 1.67x in total, whereas SP Refractories IPO subscribed 7.24x.

 Evoq Remedies IPOSP Refractories IPO
NII (times)0.30x5.64x
RII (times)3.03x8.85x
Total (times)1.67x7.24x

Compare with others

Compare: